Company Overview

Curative Biosciences, Inc. (OTC: CBDX) is a publicly traded biotechnology and wellness-focused company that has historically operated in the cannabinoid, nutraceutical, and health sciences sectors. Public disclosures indicate that the company has pursued business activities involving cannabinoid-based products, bioscience research initiatives, and intellectual property development tied to therapeutic and wellness applications. The company trades on the OTC market and has been associated with efforts to reposition itself from earlier cannabis-oriented operations toward broader bioscience and health-related commercialization strategies.

The company’s reported business model has centered on developing or acquiring health-focused products, licensing opportunities, and related commercial assets. Available public filings and OTC disclosures suggest that management has explored strategic transactions, restructuring initiatives, and partnerships intended to expand beyond commodity cannabis exposure into higher-margin bioscience and therapeutic opportunities. Data regarding long-term commercial scale, sustained operating revenue, and market share remains limited in publicly available filings, and certain operational details are inconclusive based on available public sources.

Business Operations

Curative Biosciences has historically reported operations tied to cannabinoid wellness products, bioscience research activities, and intellectual property development. Public filings indicate that the company has evaluated opportunities involving nutraceutical formulations, hemp-derived compounds, and potential therapeutic applications. Revenue generation historically appears to have been limited and evolving, with the company periodically restructuring business priorities and corporate direction. Data concerning consistently active operating segments, material recurring revenue streams, and large-scale manufacturing infrastructure is inconclusive based on available public sources.

The company’s operations appear primarily U.S.-focused, though earlier corporate activity and legacy business relationships included international cannabinoid distribution exposure. Public disclosures do not currently indicate large-scale global production assets or major multinational operating divisions comparable to larger pharmaceutical or biotechnology firms. Information regarding significant joint ventures, large subsidiaries, or material strategic partnerships remains limited in verified public reporting. Any references to prior affiliated operations should be viewed in the context of evolving corporate restructuring and OTC-market disclosure practices.

Strategic Position & Investments

Curative Biosciences has publicly positioned itself around opportunities in cannabinoid science, wellness innovation, and potential therapeutic development. Company communications and filings have referenced efforts to identify acquisition opportunities, intellectual property assets, and commercialization pathways connected to bioscience applications. Management has also discussed strategic repositioning intended to differentiate the company from lower-margin cannabis commodity businesses by focusing on research-driven products and healthcare-oriented market segments.

Publicly available information indicates that the company has explored partnerships and corporate restructuring initiatives as part of its broader strategic direction. However, independently verifiable details regarding completed large-scale acquisitions, material portfolio holdings, or substantial institutional investment activity remain limited. Data concerning proprietary technology platforms, clinical-stage therapeutic programs, or significant research commercialization outcomes is inconclusive based on available public sources.

Geographic Footprint

Curative Biosciences is headquartered in the United States and primarily operates through U.S.-based corporate and OTC market activities. Historical disclosures suggest some connection to broader North American cannabinoid and wellness markets, including prior business relationships involving cross-border industry participation. The company’s investor-facing activities and regulatory disclosures have largely been tied to U.S. reporting and OTC market compliance frameworks.

The company does not appear to maintain a large multinational operational footprint based on available public records. Verified evidence of substantial physical operations across Europe, Asia-Pacific, Latin America, or the Middle East is limited. International commercial influence, where referenced historically, appears to have been tied more to distribution relationships or strategic positioning than to major owned operating infrastructure.

Leadership & Governance

Publicly available disclosures indicate that Curative Biosciences has experienced leadership and strategic transitions associated with its evolving corporate direction. As with many OTC-listed development-stage companies, executive leadership and governance structures have changed over time in connection with restructuring efforts, financing initiatives, and business repositioning. The company’s stated strategic emphasis has generally focused on pursuing growth opportunities in bioscience, cannabinoid-related wellness applications, and intellectual property development.

Key executive and governance information available through public filings and OTC disclosures includes:

• Michael Jenkins – Chief Executive Officer
• Brian Cuban – Advisory and strategic affiliation referenced in public company communications

Additional executive and board information is limited in consistently updated public disclosures. Data concerning broader executive leadership composition, long-term governance structure, and independently verified strategic management frameworks is inconclusive based on available public sources.